» Articles » PMID: 19359218

CARD9 Versus CARMA1 in Innate and Adaptive Immunity

Overview
Journal Trends Immunol
Date 2009 Apr 11
PMID 19359218
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear factor-kappaB (NF-kappaB) and mitogen-activated protein kinases (MAPKs) are activated upon engagement of a wide variety of immunoreceptors. Accumulating evidence has demonstrated that B-cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue (MALT1) are essential signaling components for NF-kappaB and MAPK activation mediated by immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors in both adaptive and innate immunity. Recent studies have revealed that two caspase-recruitment domain (CARD) family adaptor molecules, CARD-containing MAGUK protein 1 (CARMA1) and CARD9, are crucial regulators of the ITAM-mediated signaling pathway by forming a complex with BCL10-MALT1 in lymphoid and myeloid cells, respectively. Here, we describe the immune responses and the cell-type-specific regulation mechanisms for NF-kappaB and MAPK activation controlled by CARMA1 and CARD9 through innate and adaptive immunoreceptors.

Citing Articles

Deletion of Card9 eliminates the detrimental facets of mycobacterial adjuvants.

Mitsuyama H, Iizasa E, Kukita A, Toda S, Yoshida H, Inoue H Heliyon. 2024; 10(19):e38139.

PMID: 39386804 PMC: 11462255. DOI: 10.1016/j.heliyon.2024.e38139.


CARD9 in the pathogenesis of axial spondyloarthritis.

Seufert A, Struthers H, Caplan L, Napier R Best Pract Res Clin Rheumatol. 2024; 38(2):101964.

PMID: 38897880 PMC: 11534080. DOI: 10.1016/j.berh.2024.101964.


Inherited Human BCL10 Deficiencies.

Alsaidalani A, Garcia-Solis B, Bukhari E, Van Den Rym A, Lopez-Collazo E, Sanchez-Ramon S J Clin Immunol. 2023; 44(1):13.

PMID: 38129623 PMC: 10966939. DOI: 10.1007/s10875-023-01619-z.


Genetic association of PRKCD and CARD9 polymorphisms with Vogt-Koyanagi-Harada disease in the Chinese Han population.

Zhou C, Cai S, Xie Y, Zeng Z, Zhang J, Su G Hum Genomics. 2023; 17(1):9.

PMID: 36782298 PMC: 9926551. DOI: 10.1186/s40246-023-00459-7.


CARMA3: A potential therapeutic target in non-cancer diseases.

Gui Z, Zhang Y, Zhang A, Xia W, Jia Z Front Immunol. 2023; 13:1057980.

PMID: 36618379 PMC: 9815110. DOI: 10.3389/fimmu.2022.1057980.